NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
78.96 -0.04 (-0.05%) GOLD FUTURES
2,312.30 +1.30 (+0.06%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,157.50 +1,497.59 (+3.28%)
NVO Jan 2025 170.000 call
| Previous close | 4.3000 |
| Open | 3.3500 |
| Bid | 2.9300 |
| Ask | 3.1000 |
| Strike | 170.00 |
| Expiry date | 2025-01-17 |
| Day's range | 3.3500 - 3.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 263 |
- Yahoo Finance Video
Novo Nordisk slides while Moderna pops: Tale of two pharma stocks
Pharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall Street's profit expectations, Novo Nordisk shares are sinking as the company fell short of estimates for its popular GLP-1 weight-loss drug, Wegovy. Meanwhile, Moderna is on the rise even after reporting first quarter losses. Moderna's growth is largely due to an uptick in coronavirus boosters and an expansion into the Brazillian market. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
Barrons.comNovo Nordisk’s Wegovy Sales More Than Doubled. Why the Stock Is Falling.
The Danish pharmaceutical firm, Europe’s most valuable company, said sales of the weight-loss drug jumped 106% in the first quarter.
Investor's Business DailyNovo Nordisk Dips After Wegovy Sales Double, But Miss Analysts' Forecast
Novo Nordisk stock dipped Thursday after sales of weight-loss drug, Wegovy, nearly doubled, but missed even more bullish expectations.
